Compare GROY & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROY | URGN |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 922.1M |
| IPO Year | 2020 | 2016 |
| Metric | GROY | URGN |
|---|---|---|
| Price | $3.30 | $17.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $5.90 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 2.8M | 781.6K |
| Earning Date | 03-18-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $147.12 | $127.17 |
| Revenue Next Year | $51.16 | $73.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.23 | $3.42 |
| 52 Week High | $5.45 | $30.00 |
| Indicator | GROY | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 35.82 |
| Support Level | $3.03 | $17.07 |
| Resistance Level | $4.01 | $20.44 |
| Average True Range (ATR) | 0.19 | 0.89 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 19.55 | 12.96 |
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.